Replies to post #393984 on Innovation Pharmaceuticals Inc (IPIX)

[sunspotter]

“Brilacidin plus Caspofunginon cleared infection in the lungs by almost 95 percent, compared to ~50 percent when each compound was administered individually.”

Just so no one is given the false impression this study relates to humans, the lungs in question were those of immunosuppressed mice.

While this seems like progress - for some unfathomable reason it seems like no in vivo animal models were run for brilacidin in COVID19 - that’s a long way from proving efficacy in humans.

[SitTight]

Invasive pulmonary aspergillosis (IPA) is a severe fungal infection with a high mortality rate.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318821/#:~:text=Invasive%20pulmonary%20aspergillosis%20(IPA)%20is,receiving%20chemotherapy%20and%20immunosuppressive%20therapy.

In an A. fumigatus immunosuppressed mouse model in invasive pulmonary aspergillosis, Brilacidin plus CAS cleared infection in the lungs by almost 95 percent, compared to ~50 percent when each compound was administered individually.

http://www.ipharminc.com/press-release/2022/10/3/innovation-pharmaceuticals-announces-publication-of-scientific-article-on-the-antifungal-activity-of-brilacidin

Since Brilacidin was greenlighted for "compassionate use" by the FDA for Covid, why not apply for the same for IPA? There's no risk for the patients, but a tremendous chance of recovery.

Simply give IPA patients Brilacidin alongside CAS (both intravenously) and see what happens. We would get tremendously fast real results and we do not need Merck's approval or any deal with them. All we need for this is the FDA's expansion for "compassionate use" from Covid to IPA.

[olden_grumpini]

The science is interesting and ~95% reduction is impressive but, if you read the paper and understand how much brilacidin was used, you might question whether this result has any clinical application.

Here’s the full quote from the paper (go to the paper if you want to see the figure):

Finally, we investigated if BRI+CAS could impact A. fumigatus virulence in a chemotherapeutic murine model of IPA. Fungal burden in the lungs was approximately 50% reduced after 3 days post-infection in mice treated either with CAS (1mg/kg) or BRI (50 mg/kg) when compared with the non-treated mice (Figure 5C). However, the combination of BRI+CAS significantly reduced the fungal burden by ~95% when compared with the non-treated mice (Figure 5C). These results strongly indicate that the combination BRI+CAS is able to clear A. fumigatus infection in the lungs in a chemotherapeutic murine model of IPA.

Taken together, these data indicate that the combination treatment of BRI+CAS is non-toxic to mammalian cells in vitro and is able to enhance clearance of A. fumigatus infection in pulmonary cells in vitro and in vivo when compared to monotherapy alone.

They used a dose of 50 mg/kg of brilacidin.

For comparison, the P2 ABSSSI trial that CTIX did used a maximum dose of brilacidin of 1.2 mg/kg spread out over 3 days (0.6 mg/kg on day one followed by 0.3 mg/kg on days 2 and 3). The 50 mg/kg used in the paper is >40X that dose.

The P2 ABSSSI trial that Polymedix did, where they admitted that their dosing was too high, used a maximum dose of brilacidin of 2.4 mg/kg spread out over 5 days (1.0 mg/kg on day one followed by 0.35 mg/kg daily for four days). The 50 mg/kg used in the paper is >20X that dose.